DADLE
Also known as: [D-Ala2, D-Leu5]-Enkephalin, [D-Ala2, D-Leu5]enkephalin, 63631-40-3, D-Ala(2)-Leu(5)-Enkephalin, DADLE, Tyr-D-Ala-Gly-Phe-D-Leu
Source DADLE at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
DADLE ([D‑Ala2, D‑Leu5]enkephalin) is a synthetic tetrapeptide that mimics endogenous enkephalins. It is used experimentally to study δ‑opioid receptor pharmacology, analgesia, neuroprotection, and cardiovascular effects. It has not received regulatory approval for therapeutic use.
Mechanism of Action
selective delta‑opioid receptor (δ1) agonist; also modest mu‑opioid receptor activity at higher concentrations
Routes of Administration
Goals & Uses
- NeuroprotectionNeurologyLow
- Cardioprotection / ischemia-reperfusion injuryCardiovascularModerate
- AntinociceptionResearch / AnalgesiaModerate
- Organ preservationResearch / TransplantationLow
- Induction of hibernation-like stateResearch / Suspended AnimationLow
- Opioid receptor pharmacology toolResearch / Receptor CharacterizationHigh
- AnalgesiaPain ManagementModerate
Contraindications
- concomitant CNS depressantsPharmacologicModerate
- Human therapeutic useRegulatory/safetyHigh
- Respiratory compromiseClinical (preclinical Extrapolation)High
Adverse Effects
- Cardiovascular depressionCardiovascularUncommon
- Tolerance developmentPharmacologicalUncommon
- Respiratory depressionRespiratoryCommon
- Sedation / CNS depressionNeurologicalCommon
- SedationCNSCommon
- Tolerance and dependencePharmacologicalUnknown
Drug Interactions
- CNS depressantsHigh
- BenzodiazepinesLow
- other opioids (e.g., morphine)Moderate
- Naloxone / NaltrexoneLow
Population Constraints
- Humans (general)Regulatory / SafetyAbsolute
- human clinical useClinicalAbsolute
- Pregnant animalsReproductiveRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization; used in pre‑clinical studies.
- United StatesUnapprovedInvestigational research chemical; not scheduled as a controlled substance but used under institutional review.
- United KingdomUnapprovedClassed as a research peptide; not for therapeutic use.
No approved medical indication; classified as an investigational research compound in most jurisdictions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is DADLE?
DADLE ([D‑Ala2, D‑Leu5]enkephalin) is a synthetic tetrapeptide that mimics endogenous enkephalins. It is used experimentally to study δ‑opioid receptor pharmacology, analgesia, neuroprotection, and cardiovascular effects. It has not received regulatory approval for therapeutic use.
What is DADLE used for?
DADLE is educationally associated with: Neuroprotection, Cardioprotection / ischemia-reperfusion injury, Antinociception, Organ preservation, Induction of hibernation-like state, Opioid receptor pharmacology tool, Analgesia. Educational only — not medical advice.
How is DADLE administered?
Recorded routes of administration: Intracerebroventricular, Intrathecal, Intravenous, Subcutaneous.
What are the potential side effects of DADLE?
Reported adverse effects include: Cardiovascular depression, Tolerance development, Respiratory depression, Sedation / CNS depression, Sedation, Tolerance and dependence. This list is not exhaustive — consult a qualified clinician.
Who should avoid DADLE?
Recorded contraindications: concomitant CNS depressants, Human therapeutic use, Respiratory compromise. Consult a qualified clinician before use.